This inventor holds 1 USPTO granted patent. Top assignee: Janssen Biotech, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jason Lee Dehart: Innovator in Prostate Cancer Research
Introduction
Jason Lee Dehart is a notable inventor based in San Diego, CA. He has made significant contributions to the field of cancer research, particularly in the development of innovative treatments for prostate cancer. His work focuses on the use of self-replicating RNA molecules to create vaccines that target prostate neoantigens.
Latest Patents
Dehart holds a patent for "Prostate neoantigens and their uses." This patent discloses self-replicating RNA molecules encoding prostate neoantigens, along with vaccines and methods for treating and preventing prostate cancer using these innovative RNA molecules and vaccines. He has 1 patent to his name, showcasing his commitment to advancing medical science.
Career Highlights
Jason Lee Dehart is currently employed at Janssen Biotech, Inc., where he continues to work on groundbreaking research in the field of oncology. His role at the company allows him to collaborate with other experts in the field and contribute to the development of new therapeutic strategies.
Collaborations
Throughout his career, Dehart has worked alongside talented colleagues, including Vipul Bhargava and Patrick Wilkinson. These collaborations have been instrumental in driving forward the research and development of innovative cancer treatments.
Conclusion
In summary, Jason Lee Dehart is a dedicated inventor whose work in prostate cancer research is paving the way for new treatment options. His innovative approach and collaboration with other experts highlight the importance of teamwork in scientific advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
